A Message from David Epstein
CEO & President, Novartis Oncology

Open doors and open minds make for the best workplaces. With this approach at Novartis Oncology, we’ve seen how open dialogue with patients, physicians, caregivers, and our employees drives continuous scientific and commercial innovation.

Our vision is to improve and extend the lives of cancer patients as we strive to make innovative therapies broadly available. With seven key marketed brands and six novel compounds in or about to enter registration trials, we have a proven track record and a pipeline that is both broad and deep. Building on our groundbreaking work in targeted therapies, exemplified by the modern oncology phenomenon Glivec®, today we have more than 150 clinical trials underway across our compounds and brands.

Our employees share a passion and determination to beat cancer. Novartis scientists around the world are exploring novel compounds in all phases of development and pioneering both small molecules and antibodies that we hope will further improve the way cancer is treated.

Fighting cancer requires strong partners. As an integral member of the oncology community, we work with healthcare professionals, academia, government, patient groups and all others who share our vision. Together, we are making a difference for cancer patients today, while driving the innovation and discovering the insights needed to make an even greater difference for patients tomorrow.